BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 3698013)

  • 1. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
    Mauldin SK; Husain I; Sancar A; Chaney SG
    Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
    Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
    Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of carrier ligand in platinum resistance in L1210 cells.
    Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
    Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
    Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
    Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nucleic acid synthesis in P388 lymphocytic leukemia cells in culture by cis-platinum derivatives.
    Oswald CB; Chaney SG; Hall IH
    Biomed Biochim Acta; 1990; 49(7):579-87. PubMed ID: 1704216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
    Gibbons GR; Kaufmann WK; Chaney SG
    Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
    Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
    Farrell N; Kelland LR; Roberts JD; Van Beusichem M
    Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
    Gibbons GR; Wyrick S; Chaney SG
    Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
    Luo FR; Wyrick SD; Chaney SG
    Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effectivity of two diaminocyclohexane Pt-complexes.
    Balázová E; Hrubisko M; Ujházy V
    Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).
    Chaney S
    Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
    Micetich KC; Barnes D; Erickson LC
    Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
    Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
    Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.